Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Conducted in adult T2DM patients with inadequate glycemic control after diet and exercise intervention, the results demonstrate...
First Mold’s U.S. Mold Exports Rise 30% in 2025, Driven by Electronics, Automotive, and Medical Manufacturing Demand
ZHONGSHAN, China, Jan. 28, 2026 /PRNewswire/ -- First Mold has announced an increase in its market share. In their recent report, the company announced that in 2025, it shipped over 650 mold units to the US, recording a 30% increase in exports. This announcement shows that First Mold has expanded its manufacturing footprint in the US, positioning it as...
CHCC 2026 Opens Registration, Offering a One-Stop Platform for Hospital Construction Solutions and Real-World Applications
TIANJIN, China, Jan. 28, 2026 /PRNewswire/ -- The 27th China Hospital Construction Conference & International Hospital Build and Infrastructure Exposition (CHCC 2026), a globally recognized hospital construction event, will be held from May 23 to 25, 2026, at the National Convention and Exhibition Center (Tianjin), China. Having been held successfully for 26 consecutive editions, CHCC has evolved into a...
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 28, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment. Hanmi Pharmaceutical, the core operating company of Hanmi Science,...
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from baseline. The therapy is also indicated to lower the risk of major cardiovascular events*...
Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology
The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally. SINGAPORE, Jan. 28, 2026 /PRNewswire/ -- The Singapore Eye Research Institute (SERI) has achieved a landmark milestone in December 2025 by securing first place among all non-academic institutes in...
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors,...
Asthma and Allergy Drug Development Is Failing Too Often–A Translational Reset Is Needed: HKEY-AIRx™1.0
BOSTON and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0 designed to address one of the most persistent problems facing biotech leadership: why so many asthma and allergy programs with strong preclinical data fail to deliver meaningful clinical outcomes. Over the...
Home Control Signs Memorandum of Understanding with NTU Singapore to Explore AIoT Home Healthcare Ecosystem
HONG KONG, Jan. 27, 2026 /PRNewswire/ -- Home Control International Limited ("Home Control" or the "Company", together with its subsidiaries, the "Group"; Stock Code: 1747.HK) is pleased to announce that it has entered into a Strategic Memorandum of Understanding (MoU) with Nanyang Technological University, Singapore ("NTU Singapore"). The parties will negotiate and explore the possibility of cooperation and collaboration on Artificial...
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC). To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial...
